Literature DB >> 26910530

Matrix metalloproteinases: new directions toward inhibition in the fight against cancers.

Susan E King1.   

Abstract

Matrix metalloproteinases are zinc-dependent enzymes whose main function is to cleave the components of the extracellular matrix. Their overexpression is evident in all cancers but to date there is no satisfactory way to inhibit their actions. Here, we look at their types, their structures, their functions and the developing understanding we have of them in the search for ways to drug them and inhibit their actions selectively. We investigate their subtle but exploitable differences in order that we can develop drugs to target them and even to target specific substrates and functions that they carry out. To date there are no new matrix metalloproteinase inhibitors developed to treat cancer, but we are progressing in our understanding of them, which is leading us ever closer to our goal.

Entities:  

Keywords:  allosteric inhibition; angiogenesis; epithelial to mesenchymal transition; extracellular matrix; specificity loop; zinc-binding groups; zymogens

Mesh:

Substances:

Year:  2016        PMID: 26910530     DOI: 10.4155/fmc.15.184

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  3 in total

1.  The constitutive protease release by primary human acute myeloid leukemia cells.

Authors:  Maria Honnemyr; Øystein Bruserud; Annette K Brenner
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-19       Impact factor: 4.553

2.  Tat-NTS Suppresses the Proliferation, Migration and Invasion of Glioblastoma Cells by Inhibiting Annexin-A1 Nuclear Translocation.

Authors:  Zhenzhao Luo; Li Liu; Xing Li; Weiqun Chen; Zhongxin Lu
Journal:  Cell Mol Neurobiol       Date:  2021-08-03       Impact factor: 4.231

3.  Effects of serum from breast cancer surgery patients receiving perioperative dexmedetomidine on breast cancer cell malignancy: A prospective randomized controlled trial.

Authors:  Yan Liu; Jiaxin Sun; Tong Wu; Xiaoying Lu; Yueyao Du; Hongwei Duan; Weifeng Yu; Diansan Su; Jinsong Lu; Jie Tian
Journal:  Cancer Med       Date:  2019-10-30       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.